Esther Hagai has over 15 years’ experience in Drug development both from Pharma and Biotech companies in leading global Clinical development of innovative drugs – small molecules, biologic and cell therapy.
She was previously Vice President of Clinical and Regulatory Affairs at Pluristem Ltd, an Israeli Biotechnology Company developing placental cells for ischemic, orthopedic and hemato-oncologic indications. She built the clinical and regulatory department and brought the most advanced product to pivotal trials taking advantage of early approval regulatory pathways in Europe and US as well as in Japan.
Prior to that, Esther worked at Teva Pharmaceuticals in Global R&D where she was Director, Clinical Program Leader, leading the global clinical development of innovative drugs in Pain, neurodegenerative diseases (Parkinson, Huntington and Multiple System Atrophy) and cocaine addiction. She previously also worked at Gertner Institute at Sheba Medical Center where she was responsible of clinical trials in orthopedic and hemato-oncologic indications in collaboration with NIH.
Esther holds a M.D. and a Medical Residency in Public Health from Necker-Enfants Malades Paris V School of Medicine. In addition, she holds a Master of Methodology and Statistics in Clinical Research and a M. Med. Sc. in Biostatistics and Epidemiology from Paris XI as well as a Ph.D. in Biostatistics from Bar-Ilan University.
